A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

NCT05953584 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Etavopivat
DRUG: Hydroxyurea

Sponsor

Forma Therapeutics, Inc.